- Sylvia M Lee: Clinical Research Division, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington 98109, USA.
The unique promise of latency-associated peptide resides in its selective presence on regulatory T cells (Treg) in the activated setting after patients are treated with immunomodulators such as anti-CTLA-4. The improved ability to track, scrutinize, and potentially target Tregs in this manipulated environment will be increasingly critical in developing immune-based therapies for patients with cancer.